Currently, systemic delivery of drugs for PMS is limited by the inability of drugs to cross the blood-brain-barrier (BBB). The PMSMatTrain project will develop new technology that allows controlled and targeted delivery of therapeutic molecules directly to the brain cortical tissue, exploiting “tuneable” biomaterials that allow a multi-phasic delivery of therapeutics from a minimally-invasive implantable device in the skull. Aimed specifically at generating drug regimes for treatment of the later progressive phases of MS, cocktails of anti-inflammatory agents and molecules that promote repair and protect neurones will be studied using cutting-edge models of disease pathology, in silico modelling of drug release and dispersal and development of a scaffold-based medical device.